Cell News and Research

RSS

Clinical need, effectiveness, fairness should drive drugs allocation

A policy that is transparent, fair to patients and healthcare providers, and is based on clinical need is an ethically justifiable approach to rationing drugs that are in critically short supply, report researchers.

1 Oct 2012

Addition of ficlatuzumab to gefitinib may be effective in select subsets of patients with NSCLC

AVEO Oncology today announced that detailed results from an exploratory, randomized Phase 2 study evaluating the combination of ficlatuzumab, the company's HGF inhibitory antibody, and gefitinib compared to gefitinib monotherapy in previously untreated Asian subjects with non-small cell lung cancer (NSCLC) were presented at the 2012 Congress of the European Society for Medical Oncology (ESMO).

1 Oct 2012

Medistem initiates collaboration with Superview Biotechnology

Medistem Inc announced today the initiation of a collaboration with Superview Biotechnology Co. Ltd, a subsidiary of Yinhuan Holding Co from Yixing, China.

1 Oct 2012

Takeda, Seattle Genetics announce preliminary data from brentuximab vedotin phase I study on sALCL

Millennium: The Takeda Oncology Company, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, and Seattle Genetics, Inc., today announced preliminary data from one arm of a three arm phase I, open-label, multicenter study designed to determine the safety and activity of sequential and combination treatment approaches of brentuximab vedotin with CHOP or CH-P chemotherapy in newly diagnosed patients with CD30-positive mature T- and NK- cell lymphomas.

1 Oct 2012

Nova Scotia's stroke strategy improves care for three rural health districts

Stroke patients in rural Nova Scotia receive better treatment and are less likely to end up in long-term care facilities than they were before the province's stroke strategy was rolled out in 2008, according to a study presented today at the Canadian Stroke Congress.

1 Oct 2012

Emergency medicine residency programs need more formal stroke training

Medical residents training to work in the emergency department need more formal stroke training, says a study presented today at the Canadian Stroke Congress, noting that, as the first point of contact in stroke care, they see nearly 100 per cent of stroke patients taken to hospital.

1 Oct 2012

Most people completely unaware of aphasia

Most people are completely unaware of one of stroke's most common, debilitating but invisible impairments, according to the first awareness survey of its kind in Canada released today at the Canadian Stroke Congress.

1 Oct 2012

Inhibiting DUSP6 protein can restore immune cells’ responsiveness to a more youthful state

The older we get, the weaker our immune systems tend to become, leaving us vulnerable to infectious diseases and cancer and eroding our ability to benefit from vaccination. Now Stanford University School of Medicine scientists have found that blocking the action of a single protein whose levels in our immune cells creep steadily upward with age can restore those cells' response to a vaccine.

1 Oct 2012

Home delivery of stroke rehabilitation improves care, eliminates waiting lists and saves costs

Home delivery of stroke rehabilitation improves care, eliminates waiting lists for treatment and saves hundreds of thousands of dollars annually in hospital costs, according to a quality improvement project presented today at the Canadian Stroke Congress.

1 Oct 2012

Cafeteria diet increases risk of stroke or death at a younger age

The fat- and sugar-rich Western diet leads to a lifetime of health problems, dramatically increasing the risk of stroke or death at a younger age, according to a study presented today at the Canadian Stroke Congress.

1 Oct 2012

Active Biotech, Ipsen announce new data on biomarkers from tasquinimod Phase II study in CRPC

Active Biotech and Ipsen have presented a new set of data on biomarkers from the previously concluded tasquinimod Phase II study in chemotherapy-naïve metastatic castrate resistant prostate cancer (CRPC) at the scientific congress ESMO (European Society for Medical Oncology) held in Vienna September 28-October 2.

1 Oct 2012

Exelixis announces interim data from cabozantinib phase 2 trial on metastatic CRPC

Exelixis, Inc. today announced interim data from 51 patients with metastatic castration-resistant prostate cancer (CRPC) and bone metastases receiving a 40 mg daily dose of cabozantinib in an ongoing non-randomized expansion (NRE) cohort of a phase 2 randomized discontinuation trial.

1 Oct 2012

Researchers identify how p110delta molecule controls the body's inflammatory responses

Researchers at Queen Mary, University of London have discovered how a key molecule controls the body's inflammatory responses. The molecule, known as p110delta, fine-tunes inflammation to avoid excessive reactions that can damage the organism.

1 Oct 2012

Combination of dabrafenib and trametinib delays development of treatment resistance in MM patients

Combined treatment with two drugs targeting different points in the same growth-factor pathway delayed the development of treatment resistance in patients with BRAF-positive metastatic malignant melanoma.

1 Oct 2012

Crizotinib effectively treats patients with ALK-positive lung cancer

The results of a new phase III trial show that crizotinib, a targeted therapy, is a more effective treatment than standard chemotherapy for patients with advanced, ALK-positive lung cancer, researchers said at the ESMO 2012 Congress of the European Society for Medical Oncology in Vienna.

1 Oct 2012

Exercise can improve overall brain function following stroke

Just six months of exercise can improve memory, language, thinking and judgment problems by almost 50 per cent, says a study presented today at the Canadian Stroke Congress.

1 Oct 2012

Common RNA pathway links frontotemporal lobar dementia with ALS

Two proteins previously found to contribute to ALS, also known as Lou Gehrig's disease, have divergent roles. But a new study, led by researchers at the Department of Cellular and Molecular Medicine at the University of California, San Diego School of Medicine, shows that a common pathway links them.

1 Oct 2012

Cell News and Research

Clinical need, effectiveness, fairness should drive drugs allocation

Addition of ficlatuzumab to gefitinib may be effective in select subsets of patients with NSCLC

Medistem initiates collaboration with Superview Biotechnology

Takeda, Seattle Genetics announce preliminary data from brentuximab vedotin phase I study on sALCL

Nova Scotia's stroke strategy improves care for three rural health districts

Emergency medicine residency programs need more formal stroke training

Most people completely unaware of aphasia

Inhibiting DUSP6 protein can restore immune cells’ responsiveness to a more youthful state

Home delivery of stroke rehabilitation improves care, eliminates waiting lists and saves costs

Cafeteria diet increases risk of stroke or death at a younger age

Active Biotech, Ipsen announce new data on biomarkers from tasquinimod Phase II study in CRPC

Exelixis announces interim data from cabozantinib phase 2 trial on metastatic CRPC

Researchers identify how p110delta molecule controls the body's inflammatory responses

Combination of dabrafenib and trametinib delays development of treatment resistance in MM patients

Crizotinib effectively treats patients with ALK-positive lung cancer

Exercise can improve overall brain function following stroke

Common RNA pathway links frontotemporal lobar dementia with ALS

Exelix reports preliminary data from cabozantinib phase 1 study on solid tumors

CIB2 genetic mutation responsible for deafness associated with Usher syndrome type 1

New trial results on pazopanib and temsirolimus have important implications for patients with RCC

How to optimize your cell line development eBook

Latest eBooks

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics